5. Conclusions
CD is still considered a global health problem with significant
epidemiological and socioeconomic implications. In recent years,
technical advances in several areas have contributed to a better
understanding of the biology and life cycle of this parasite, which will
make it possible to design the ideal profile of both drugs and
therapeutic options for treating CD. Here, we present T. cruziArequipa strain as an interesting tool for drug discovery against CD.
For in vitro assays, several different strains should be used for
the evaluation of the spectrum of action of potential compounds.
However, for in vivo assays, and in order to fulfil the
principles of the 3Rs (Replacement, Reduction and Refinement) in animal
research, T. cruzi Arequipa can be the strain of choice. The
tropism of this strain makes it ideal for the evaluation of potential
compounds with the aim of selecting those with the best anti-Chagas
profile.